Viral Vector Epidermal Vaccination via Scarification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines, particularly for pathogens like HIV, HCV, TB, malaria, dengue fever, and cancer, are ineffective in inducing T cell-mediated immunity and can be harmful to immunosuppressed individuals, and traditional delivery methods require high doses and multiple injections for limited protection.
Innovation Solution
Attenuated, replication-deficient viruses like vaccinia viruses are used to deliver antigens to mechanically disrupted epidermal tissues, such as the skin or lungs, to stimulate a cell-mediated immune response, with optional co-administration of co-stimulatory molecules, growth factors, or cytokines, and the use of a scarification device for mechanical disruption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional injection routes are used to deliver vaccines, then the vaccine can be administered, but the immune response is weak and multiple high-dose injections are required
Solution Approach 1:
The patent uses attenuated viruses as intermediary carriers to deliver antigenic material to epidermal tissue. These viral vectors naturally target and infect epidermal cells, serving as biological mediators that efficiently transport the vaccine payload to the desired location without requiring direct injection into deeper tissues
Solution Approach 2:
The patent transitions from conventional intramuscular or subcutaneous injection routes to epidermal delivery via mechanical disruption. This represents a dimensional shift from deep tissue injection to surface-level epidermal application, utilizing the epidermis as a new delivery dimension that provides direct access to immune cells
2Reliability
If conventional injection routes are used to deliver vaccines, then the vaccine can be administered, but multiple injections are required for adequate protection
Solution Approach 1:
The patent employs mechanical disruption of the epidermis prior to vaccine application to pre-open delivery pathways. This preliminary action creates micro-channels and increases epidermal permeability, allowing the vaccine to be efficiently absorbed in a single application without requiring multiple injection sessions
3Object-affected harmful factors
If killed vaccines are used, then the vaccine is safe for immunosuppressed subjects, but T cell-mediated immunity is not induced
Solution Approach 1:
The patent uses attenuated viruses with modified replication capabilities that are reduced but not completely eliminated. This parameter change allows the vaccine to maintain enough biological activity to induce T cell responses while being sufficiently attenuated to ensure safety for immunosuppressed populations
Solution Approach 2:
The patent delivers the attenuated vaccine directly to epidermal tissue where it can locally stimulate immune responses. The localized delivery to the epidermis creates a controlled environment that induces T cell-mediated immunity without requiring systemic administration that might pose risks to immunosuppressed subjects
Data Source
AI summary
Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The epidermal tissue may be mechanically disrupted by a device such as a scarification needle or an abrader device. The epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine. The vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer. In some embodiments a co-stimulatory molecule, a growth factor, an adjuvant and/or a cytokine is administered before, with or after the viral vaccine. In some embodiments, the co-stimulatory molecule is co-expressed with the antigen by the virus.